(Bloomberg) A case brought by a U.S. hedge fund against China’s Global Cord Blood Corp. may set a precedent in the Cayman Islands for other minority shareholders who feel shortchanged by all-share mergers.
Hedge Fund Fights Over Stem-Cell Company’s Value in Cayman Court
This entry was posted in Syndicated. Bookmark the permalink.
